Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 181Terminated 59Unknown 20Withdrawn 10Active not recruiting 3Recruiting 2Approved for marketing 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Head & Neck 1

Conditions

Breast Neoplasms 2Thyroid Neoplasms 1Patient Compliance 1

Interventions

pembrolizumab 437Carboplatin 322Nivolumab 292Cyclophosphamide 281Specimen Handling 271Magnetic Resonance Spectroscopy 257Cisplatin 253Paclitaxel 248Radiotherapy 229Gemcitabine 183Biopsy 182Dexamethasone 181durvalumab 168atezolizumab 151Rituximab 138Doxorubicin 135Lenalidomide 134Bevacizumab 133Docetaxel 131Ipilimumab 129Capecitabine 120Radiation 118Oxaliplatin 114Radiosurgery 113Pemetrexed 112Etoposide 111Fluorouracil 110venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Lapatinib × Clear all
NCT01947023 2026-05-14

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
23 enrolled
Head & Neck

Thyroid Neoplasms

NCT01273610 2025-06-10

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
40 enrolled 15 charts
Breast

Breast Neoplasms, Patient Compliance

NCT00999804 2025-03-12

HELEX

Baylor Breast Care Center

Phase 2 Active not recruiting
128 enrolled 11 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡